Document is current
Any future updates will be listed below
-
Authors
De Strooper, Bart https://orcid.org/0000-0001-5455-5819
Karran, Eric
-
Funding
Funding for this research was provided by:
EC | European Research Council (ERC-834682)
UK Research and Innovation (MR/Y014847/1)
Fonds Wetenschappelijk Onderzoek
Methusalem grant KULeuven
Queen Elisabeth Medical Foundation for Neurosciences
Belgian Alzheimer Research Foundation
The Alzheimer’s Association USA
Opening the Future
Bax-Van Luffelen foundation
- License Information
-
More Information
Article History
Received: 18 November 2023
Revised: 20 January 2024
Accepted: 6 February 2024
First Online: 23 February 2024
Disclosure and competing interests statement
: EK is an employee and stockholder of AbbVie. BDS is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie, and other companies. BDS is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. BDS is a member of the Advisory Editorial Board of The EMBO Journal. This has no bearing on the editorial consideration of this article for publication.
